002038 Beijing Sl Pharmaceutical
- 7.83
- +0.07+0.90%
Beijing Sl Pharmaceutical News
Shuanglu Pharmaceutical (002038) First Coverage Report: Promoting the Construction of Multiple Product Lines
Shuanglu Pharmaceutical Co., Ltd. (002038): affected by higher-than-expected expenses, the annual net profit of returning home waits for change.
Shuanglu Pharmaceutical (002038) Quarterly report comments: the performance is in line with expectations and the main varieties are expected to stabilize.
Shuanglu Pharmaceutical Co., Ltd. (002038) three-quarter report comments: the three-quarter report results are in line with expectations and the promotion of lenalidomide is smooth.
Shuanglu Pharmaceutical (002038) Quarterly report comments: deducting non-performance to maintain rapid growth is expected to exceed expectations for the whole year
Shuanglu Pharmaceutical (002038) report comments: the second-tier varieties maintain rapid growth and are expected to release heavy products in the future.
Shuanglu Pharmaceutical (002038) report comments: deducting non-growth performance is expected to gradually increase in the second half of the year.
Shuanglu Pharmaceutical (002038) Quarterly report comments: deducting non-net profit to achieve 64% growth performance inflection point is gradually established
Shuanglu Pharmaceutical Co., Ltd. (002038) in-depth report: the performance inflection point of lenalidomide sales is expected to appear in 2018
Shuanglu Pharmaceutical Co., Ltd. (002038) Review: progress in Variety Review of traditional Product Line under pressure expectation Reserve Variety
Shuanglu Pharmaceutical (002038) review: Lenalidomide approval progress is expected to accelerate
Review of Shuanglu Pharmaceutical (002038) Annual Report and Quarterly Report: Compound Coenzyme Performance Declines Under Pressure
Shuanglu Pharmaceutical (002038) Quarterly Report Review: The Impact of Health Insurance Fee Control Is Obvious, Waiting for Reversal Varieties to Be Approved
[Southwest Securities] Shuanglu Pharmaceutical: The impact of health insurance fee control is obvious, waiting for reversal varieties to be approved
[Anxin Securities] Shuanglu Pharmaceutical: Major products are about to be listed, reshaping the logic of high growth
Shuanglu Pharmaceutical (002038) Interim Report: The imminent launch of large varieties will reshape the logic of high growth
Shuanglu Pharmaceutical (002038) Interim Report: After experiencing the pain of product structure transformation, performance continues to decline
Shuanglu Pharmaceutical (002038) Interim Report Review: Waiting for a Performance Reversal
Shuanglu Pharmaceutical (002038) Interim Report: Lenalidomide is likely to be approved or significantly improve performance
Shuanglu Pharmaceutical (002038) Annual Report and Quarterly Report Review: Lenalidomide Receives Priority Approval and Product Reserves Are Becoming Richer
Analysis
Price Target
No Data
